ArticleLeukemia2024

CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.

Liora M Schultz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.